Panmira Pharmaceuticals, LLC. and FLAP LLC Spun Out of Amira Pharmaceuticals, Inc.
9/8/2011 3:00:17 PM
More...
|
Bristol-Myers Squibb Company (BMY) Completes Acquisition of Amira Pharmaceuticals, Inc.
9/8/2011 10:51:38 AM
More...
|
Bristol-Myers Squibb Company (BMY) to Pay Up to $475 Million for Amira Pharmaceuticals, Inc., Scoops Up Lung Drug
7/22/2011 6:32:43 AM
More...
|
Amira Pharmaceuticals, Inc. Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
5/2/2011 9:17:44 AM
More...
|
Amira Pharmaceuticals, Inc. Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
4/19/2011 7:32:48 AM
More...
|
Findings Published in Journal of Pharmacology and Experimental Therapeutics Demonstrate Potential for Amira Pharmaceuticals, Inc.'s LPA1 Receptor Antagonist as an Anti-Fibrotic Agent
1/5/2011 9:13:32 AM
More...
|
Amira Pharmaceuticals, Inc. Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
12/15/2010 11:12:11 AM
More...
|
Amira Pharmaceuticals, Inc. to Present Preclinical, Clinical Data from DP2 Receptor Antagonist Program at Pacifichem 2010
12/14/2010 10:51:02 AM
More...
|
Amira Pharmaceuticals, Inc. Cuts Half of Staff, Scientific Founders Exit as Company Seeks to Conserve Cash
11/24/2010 7:04:47 AM
More...
|
Amira Pharmaceuticals, Inc. Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
10/28/2010 10:42:30 AM
More...
|
|